IDEAS home Printed from https://ideas.repec.org/a/nat/natcom/v8y2017i1d10.1038_s41467-016-0008-7.html
   My bibliography  Save this article

CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor

Author

Listed:
  • Tyler Funnell

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Shinya Tasaki

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Arusha Oloumi

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia
    Janssen Pharmaceuticals)

  • Shinsuke Araki

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Esther Kong

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Damian Yap

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Yusuke Nakayama

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Christopher S. Hughes

    (Michael Smith Genome Sciences Centre, BC Cancer Agency)

  • S.-W. Grace Cheng

    (Michael Smith Genome Sciences Centre, BC Cancer Agency)

  • Hirokazu Tozaki

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Misa Iwatani

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Satoshi Sasaki

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Tomohiro Ohashi

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Tohru Miyazaki

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Nao Morishita

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Daisuke Morishita

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Mari Ogasawara-Shimizu

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Momoko Ohori

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Shoichi Nakao

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Masatoshi Karashima

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Masaya Sano

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Aiko Murai

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Toshiyuki Nomura

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Noriko Uchiyama

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Tomohiro Kawamoto

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Ryujiro Hara

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
    Fujirebio Inc.)

  • Osamu Nakanishi

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited
    Japan Agency for Medical Research and Development)

  • Karey Shumansky

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Jamie Rosner

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia
    Advanced Research Computing, University of British Columbia)

  • Adrian Wan

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Steven McKinney

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Gregg B. Morin

    (Michael Smith Genome Sciences Centre, BC Cancer Agency
    Department of Medical Genetics, University of British Columbia)

  • Atsushi Nakanishi

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Sohrab Shah

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

  • Hiroyoshi Toyoshiba

    (Pharmaceutical Research Division, Takeda Pharmaceutical Company Limited)

  • Samuel Aparicio

    (Department of Molecular Oncology, BC Cancer Agency
    Department of Pathology and Laboratory Medicine, University of British Columbia)

Abstract

CDC-like kinase phosphorylation of serine/arginine-rich proteins is central to RNA splicing reactions. Yet, the genomic network of CDC-like kinase-dependent RNA processing events remains poorly defined. Here, we explore the connectivity of genomic CDC-like kinase splicing functions by applying graduated, short-exposure, pharmacological CDC-like kinase inhibition using a novel small molecule (T3) with very high potency, selectivity, and cell-based stability. Using RNA-Seq, we define CDC-like kinase-responsive alternative splicing events, the large majority of which monotonically increase or decrease with increasing CDC-like kinase inhibition. We show that distinct RNA-binding motifs are associated with T3 response in skipped exons. Unexpectedly, we observe dose-dependent conjoined gene transcription, which is associated with motif enrichment in the last and second exons of upstream and downstream partners, respectively. siRNA knockdown of CLK2-associated genes significantly increases conjoined gene formation. Collectively, our results reveal an unexpected role for CDC-like kinase in conjoined gene formation, via regulation of 3′-end processing and associated splicing factors.

Suggested Citation

  • Tyler Funnell & Shinya Tasaki & Arusha Oloumi & Shinsuke Araki & Esther Kong & Damian Yap & Yusuke Nakayama & Christopher S. Hughes & S.-W. Grace Cheng & Hirokazu Tozaki & Misa Iwatani & Satoshi Sasak, 2017. "CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor," Nature Communications, Nature, vol. 8(1), pages 1-16, December.
  • Handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-016-0008-7
    DOI: 10.1038/s41467-016-0008-7
    as

    Download full text from publisher

    File URL: https://www.nature.com/articles/s41467-016-0008-7
    File Function: Abstract
    Download Restriction: no

    File URL: https://libkey.io/10.1038/s41467-016-0008-7?utm_source=ideas
    LibKey link: if access is restricted and if your library uses this service, LibKey will redirect you to where you can use your library subscription to access this item
    ---><---

    More about this item

    Statistics

    Access and download statistics

    Corrections

    All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:nat:natcom:v:8:y:2017:i:1:d:10.1038_s41467-016-0008-7. See general information about how to correct material in RePEc.

    If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.

    We have no bibliographic references for this item. You can help adding them by using this form .

    If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.

    For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Sonal Shukla or Springer Nature Abstracting and Indexing (email available below). General contact details of provider: http://www.nature.com .

    Please note that corrections may take a couple of weeks to filter through the various RePEc services.

    IDEAS is a RePEc service. RePEc uses bibliographic data supplied by the respective publishers.